Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis

INTRODUCTION: Cladribine Tablets (MAVENCLAD(®)) selectively reduce absolute lymphocyte counts (ALCs) in patients with multiple sclerosis. The recommended cumulative dose of Cladribine Tablets is 3.5 mg/kg over 4–5 days in months 1 and 2 of treatment years 1 and 2, followed by prolonged efficacy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Terranova, Nadia, Hicking, Christine, Dangond, Fernando, Munafo, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373385/
https://www.ncbi.nlm.nih.gov/pubmed/29992396
http://dx.doi.org/10.1007/s40262-018-0693-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373385/
https://www.ncbi.nlm.nih.gov/pubmed/29992396
http://dx.doi.org/10.1007/s40262-018-0693-y

Ejemplares similares